GEN1047 for Solid Tumors - First in Human (FIH) Trial
Phase 1/2 Terminated
179 enrolled
PRO1107 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
33 enrolled
A Study to Evaluate the Safety and Pharmacokinetics of OC-001 in Patients With Locally Advanced or Metastatic Cancers
Phase 1/2 Terminated
73 enrolled
A Study of PF-06873600 in People With Cancer
Phase 1/2 Terminated
155 enrolled 44 charts
Phase 1/2a Study of SQ3370 in Patients With Advanced Solid Tumors
Phase 1/2 Terminated
53 enrolled 23 charts
Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors
Phase 1/2 Terminated
8 enrolled 12 charts
Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies
Phase 1/2 Terminated
137 enrolled 31 charts
T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer
Phase 1/2 Terminated
6 enrolled 11 charts
A Study of INCB099280 in Combination With Axitinib in Adults With Advanced Solid Tumors
Phase 1/2 Terminated
5 enrolled
Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer Plus Intranodal DC Vaccines
Phase 1/2 Terminated
25 enrolled
AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
Phase 1/2 Terminated
12 enrolled 13 charts
A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
52 enrolled 33 charts
A Safety and Tolerability Study of NC762 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
40 enrolled 20 charts
A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors
Phase 1/2 Terminated
6 enrolled
A Phase 1b/2 Study of Rebastinib (DCC-2036) in Combination With Paclitaxel in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
177 enrolled 25 charts
A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
70 enrolled 24 charts
Oral AMXT 1501 Dicaprate in Combination With IV DFMO
Phase 1/2 Terminated
15 enrolled
Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1 Expression Participants
Phase 1/2 Terminated
16 enrolled 42 charts
REVOCAN
Phase 1/2 Terminated
13 enrolled
Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With Platinum-Resistant Ovarian Cancer
Phase 1/2 Terminated
10 enrolled 21 charts
PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With Carboplatin in Platinum-Resistant Epithelial Ovarian Cancer
Phase 1/2 Terminated
37 enrolled 12 charts
QUILT-3.026: AMG 655 in Combination With AMG 479 in Advanced, Refractory Solid Tumors
Phase 1/2 Terminated
89 enrolled 20 charts
Study to Evaluate TNG348 Alone and With a PARP Inhibitor in Patients With BRCA 1/2 Mutant or HRD+ Solid Tumors
Phase 1/2 Terminated
7 enrolled
A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα)
Phase 1/2 Terminated
79 enrolled
QUILT-3.040: ETBX-011 (Ad5 [E1-, E2b-]-CEA(6D)) Vaccine in Combination With ALT-803 (Super-agonist IL-15) in Subjects Having CEA-Expressing Cancer
Phase 1/2 Terminated
3 enrolled 6 charts
Dose Escalation and Efficacy Study of mRNA-2416 for Intratumoral Injection Alone and in Combination With Durvalumab for Participants With Advanced Malignancies
Phase 1/2 Terminated
79 enrolled 18 charts
A Safety and Tolerability Study of NC410 in Subjects With Advanced or Metastatic Solid Tumors
Phase 1/2 Terminated
46 enrolled 21 charts
ORCHID-1
Phase 1/2 Terminated
26 enrolled
A Study of Intraperitoneally Administered AVB-001 in Patients With Serous Adenocarcinoma of the Ovary
Phase 1/2 Terminated
14 enrolled
A Study of DSP-7888 Dosing Emulsion in Combination With Immune Checkpoint Inhibitors in Adult Patients With Advanced Solid Tumors
Phase 1/2 Terminated
47 enrolled 11 charts
A Study to Evaluate the Combination of ATX-101 and Platinum-based Chemotherapy
Phase 1/2 Terminated
16 enrolled
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
Phase 1/2 Terminated
25 enrolled 11 charts
PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors
Phase 1/2 Terminated
99 enrolled 21 charts
A Study of AK112 Combined With PARP Inhibitor in the Treatment of Recurrent Ovarian Cancer
Phase 1/2 Terminated
8 enrolled
A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours
Phase 1/2 Terminated
6 enrolled
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
Phase 1/2 Terminated
7 enrolled 9 charts
E7080 in Combination With Carboplatin + Gemcitabine Versus Carboplatin + Gemcitabine Alone as Second Line Therapy in Patients With Platinum-Sensitive Recurrent Ovarian Cancer by CA125
Phase 1/2 Terminated
7 enrolled 6 charts
Evaluation and Treatment of Iron Deficiency in Ovarian Cancer Patients
Phase 1/2 Terminated
9 enrolled
NTX-301 Monotherapy in Advanced Solid Tumours and in Combination With Platinum-based Chemotherapy in Advanced Ovarian & Bladder Cancer and in Combination With Temozolomide in High-grade Glioma
Phase 1/2 Terminated
12 enrolled
A Clinical Trial of Autologous Oxidized Tumor Cell Lysate Vaccine For Recurrent Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1/2 Terminated
3 enrolled 4 charts
Pazopanib/Doxil in Adv Relapsed Plat Sensitive or Resistant Ovarian, Fallopian or Primary Peritoneal Adenocarcinoma
Phase 1/2 Terminated
22 enrolled 12 charts
INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies
Phase 1/2 Terminated
10 enrolled 14 charts
PAZOFOS
Phase 1/2 Terminated
21 enrolled
PTX-200 and Carboplatin in Ovarian Cancer
Phase 1/2 Terminated
15 enrolled
Fenretinide/LXS Oral Powder Plus Ketoconazole in Recurrent Ovarian Cancer
Phase 1/2 Terminated
12 enrolled
A Study of CRLX101(NLG207) in Combination With Weekly Paclitaxel in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1/2 Terminated
30 enrolled
A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors
Phase 1/2 Terminated
78 enrolled 19 charts
CAR T Cell Receptor Immunotherapy Targeting Mesothelin for Patients With Metastatic Cancer
Phase 1/2 Terminated
15 enrolled 14 charts
AL3818
Phase 1/2 Terminated
12 enrolled
SEASCAPE
Phase 1/2 Terminated
35 enrolled 20 charts